M6A Regulatory Genes Play an Important Role in the Prognosis, Progression and Immune Microenvironment of Pancreatic Adenocarcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590.
   PubMed Web of Science ®Google Scholar
• Simoes PK, Olson SH, Saldia A, Kurtz RC. Epidemiology of pancreatic adenocarcinoma. Chinese Clin. 2017;6(3):24. doi:10.21037/cco.2017.06.32.
   PubMed Web of Science ®Google Scholar
• Lin QJ, Yang F, Jin C, Fu DL. Current status and progress of pancreatic cancer in China. World J Astroenterol. 2015;21(26):7988–8003. doi:10.3748/wjg.v21.i26.7988.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442.
   PubMed Web of Science ®Google Scholar
• Shaib WL, Ip A, Cardona K, Alese OB, Maithel SK, Kooby D, et al. Contemporary management of borderline resectable and locally advanced unresectable pancreatic cancer. Oncologist. 2016;21(2):178–87. doi:10.1634/theoncologist.2015-0316.
   PubMed Web of Science ®Google Scholar
• Stokes JB, Nolan NJ, Stelow EB, Walters DM, Weiss GR, de Lange EE, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 2011;18(3):619–27. doi:10.1245/s10434-010-1456-7.
   PubMed Web of Science ®Google Scholar
• Hong D, Rasco D, Veeder M, Luke JJ, Chandler J, Balmanoukian A, et al. A phase 1b/2 study of the bruton tyrosine kinase inhibitor ibrutinib and the pd-l1 inhibitor durvalumab in patients with pretreated solid tumors. Oncology. 2019;97(2):102–11. doi:10.1159/000500571.
   PubMed Web of Science ®Google Scholar
• Schultheis B, Reuter D, Ebert MP, Siveke J, Kerkhoff A, Berdel WE, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Annals Oncol Offic J Euro Soc Med Oncol. 2017;28(10):2429–35. doi:10.1093/annonc/mdx343.
   PubMed Web of Science ®Google Scholar
• Bouchart C, Navez J, Closset J, Hendlisz A, Van Gestel D, Moretti L, et al. Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard? Therapeutic Adv Med Oncol. 2020;12:1758835920936093. doi:10.1177/1758835920936093.
   Web of Science ®Google Scholar
• Pan Y, Ma P, Liu Y, Li W, Shu Y. Multiple functions of m6A RNA methylation in cancer. J Hematol Oncol. 2018;(1)11:48. doi:10.1186/s13045-018-0590-8.
   PubMedGoogle Scholar
• Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci USA. 1974;71(10):3971–3975. doi:10.1073/pnas.71.10.3971.
   PubMed Web of Science ®Google Scholar
• Wei CM, Gershowitz A, Moss B. Methylated nucleotides block 5' terminus of HeLa cell messenger RNA. Cell. 1975;4(4):379–386. doi:10.1016/0092-8674(75)90158-0.
   PubMed Web of Science ®Google Scholar
• Tuncel G, Kalkan R. Importance of m N6-methyladenosine (m6A) RNA modification in cancer . Med Oncol. 2019;36(4):36. doi:10.1007/s12032-019-1260-6.
   PubMed Web of Science ®Google Scholar
• Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nature Chem Biol. 2014;10(2):93–95. doi:10.1038/nchembio.1432.
   PubMed Web of Science ®Google Scholar
• Song Y, Xu Q, Wei Z, Zhen D, Su J, Chen K, et al. Predict epitranscriptome targets and regulatory functions of N6-Methyladenosine (m6A) writers and erasers. Evol Bioinform Online. 2019;15:1176934319871290. doi:10.1177/1176934319871290.
   Web of Science ®Google Scholar
• Zhang C, Fu J, Zhou Y. A review in research progress concerning m6a methylation and immunoregulation. Front Immunol. 2019;10:922. doi:10.3389/fimmu.2019.00922.
   PubMed Web of Science ®Google Scholar
• Cai X, Wang X, Cao C, Gao Y, Zhang S, Yang Z, et al. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g. Cancer Lett. 2018;415:11–19. doi:10.1016/j.canlet.2017.11.018.
   PubMed Web of Science ®Google Scholar
• Ma J-z, Yang F, Zhou C-c, Liu F, Yuan J-h, Wang F, et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N -methyladenosine-dependent primary MicroRNA processing. Hepatology. 2017;65(2):529–543. doi:10.1002/hep.28885.
   PubMed Web of Science ®Google Scholar
• Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase. Cancer Cell. 2017;31(1):127–141. doi:10.1016/j.ccell.2016.11.017.
   PubMed Web of Science ®Google Scholar
• He Y, Hu H, Wang Y, Yuan H, Lu Z, Wu P, et al. ALKBH5 inhibits pancreatic cancer motility by decreasing long non-coding RNA KCNK15-AS1 Methylation. Cell Physiol Biochem. 2018;48(2):838–846. doi:10.1159/000491915.
   PubMedGoogle Scholar
• Xia T, Wu X, Cao M, Zhang P, Shi G, Zhang J, et al. The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion. Pathol Res Pract. 2019;215(11):152666. doi:10.1016/j.prp.2019.152666.
   PubMed Web of Science ®Google Scholar
• Wang M, Liu J, Zhao Y, He R, Xu X, Guo X, et al. Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer. Molecular Cancer. 2020;19(1):130. doi:10.1186/s12943-020-01249-8.
   PubMed Web of Science ®Google Scholar
• Yang S, He P, Wang J, Schetter A, Tang W, Funamizu N, et al. A novel MIF signaling pathway drives the malignant character of pancreatic cancer by targeting NR3C2. Cancer Res. 2016;76(13):3838–3850. doi:10.1158/0008-5472.CAN-15-2841.
   PubMed Web of Science ®Google Scholar
• Pathan M, Keerthikumar S, Chisanga D, Alessandro R, Ang C-S, Askenase P, et al. A novel community driven software for functional enrichment analysis of extracellular vesicles data. J Extracell Vesicles. 2017;6(1):1321455. doi:10.1080/20013078.2017.1321455.
   PubMed Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259.
   PubMedGoogle Scholar
• Li B, Severson E, Pignon J-C, Zhao H, Li T, Novak J, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174. doi:10.1186/s13059-016-1028-7.
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307.
   PubMed Web of Science ®Google Scholar
• Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419.
   PubMed Web of Science ®Google Scholar
• Zhang J, Bai R, Li M, Ye H, Wu C, Wang C, et al. Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Nature Commun. 2019;(1)10:1858. doi:10.1038/s41467-019-09712-x.
   PubMedGoogle Scholar
• Miao R, Dai C-C, Mei L, Xu J, Sun S-W, Xing Y-L, et al. KIAA1429 regulates cell proliferation by targeting c-Jun messenger RNA directly in gastric cancer. J Cell Physiol. 2020;235(10):7420–7432. doi:10.1002/jcp.29645.
   PubMed Web of Science ®Google Scholar
• Guo X, Li K, Jiang W, Hu Y, Xiao W, Huang Y, et al. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner. Molecular Cancer. 2020;19(1):91. doi:10.1186/s12943-020-01158-w.
   PubMed Web of Science ®Google Scholar
• Pi J, Wang W, Ji M, Wang X, Wei X, Jin J, et al. YTHDF1 promotes gastric carcinogenesis by controlling translation of FZD7. Cancer Res. 2020. doi:10.1158/0008-5472.CAN-20-0066.
   PubMedGoogle Scholar
• Wang L, Hui H, Agrawal K, Kang Y, Li N, Tang R, et al. m6 A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J. 202:e104514.doi:10.15252/embj.2020104514.
   Google Scholar
• Lu TX, Zheng Z, Zhang L, Sun H-L, Bissonnette M, Huang H, et al. A new model of spontaneous colitis in mice induced by deletion of an RNA m6A methyltransferase component METTL14 in T cells. Cell Mol Gastroenterol Hepatol. 2020;10(4):747–761. doi:10.1016/j.jcmgh.2020.07.001.
   PubMed Web of Science ®Google Scholar
• Li N, Kang Y, Wang L, Huff S, Tang R, Hui H, et al. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci USA. 2020;117(33):20159–20170. doi:10.1073/pnas.1918986117.
   PubMed Web of Science ®Google Scholar
• Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature. 2019;566(7743):270–274. doi:10.1038/s41586-019-0916-x.
   PubMed Web of Science ®Google Scholar
• Miller AL, Garcia PL, Yoon KJ. Developing effective combination therapy for pancreatic cancer: an overview. Pharmacol Res. 2020;155:104740. doi:10.1016/j.phrs.2020.104740.
   PubMed Web of Science ®Google Scholar
• Ilango S, Paital B, Jayachandran P, Padma PR, Nirmaladevi R. Epigenetic alterations in cancer. Front Biosci. 2020;25(6):1058–1109. doi:10.2741/4847.
   PubMedGoogle Scholar
• Maity A, Das B. N6-methyladenosine modification in mRNA: machinery, function and implications for health and diseases. The FEBS Journal. 2016;283(9):1607–1630. doi:10.1111/febs.13614.
   PubMed Web of Science ®Google Scholar
• Taketo K, Konno M, Asai A, Koseki J, Toratani M, Satoh T, et al. The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Inter J Oncol. 2018;52(2):621–629. doi:10.3892/ijo.2017.4219.
   PubMed Web of Science ®Google Scholar
• Tang B, Yang Y, Kang M, Wang Y, Wang Y, Bi Y, et al. m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling. Mol Cancer. 2020;19(1):3. doi:10.1186/s12943-019-1128-6.
   PubMed Web of Science ®Google Scholar
• Wang X, Feng J, Xue Y, Guan Z, Zhang D, Liu Z, et al. Corrigendum: structural basis of N-adenosine methylation by the METTL3-METTL14 complex. Nature. 2017;542(7640):260. doi:10.1038/nature21073.
   PubMed Web of Science ®Google Scholar
• van Roessel S, Kasumova GG, Verheij J, Najarian RM, Maggino L, de Pastena M, et al. International validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system in patients with resected pancreatic cancer. JAMA Surg. 2018;153(12):e183617. doi:10.1001/jamasurg.2018.3617.
   PubMed Web of Science ®Google Scholar
• Gaitanidis A, Patel D, Nilubol N, Tirosh A, Kebebew E. A lymph node ratio-based staging model is superior to the current staging system for pancreatic neuroendocrine tumors. J Clin Endocrinol Metabol . 2018;103(1):187–195. doi:10.1210/jc.2017-01791.
   PubMed Web of Science ®Google Scholar
• Zhang X, Lu L, Liu P, Cao F, Wei Y, Ma L, Gong P. Predictive effect of the total number of examined lymph nodes on N staging and survival in pancreatic neuroendocrine neoplasms. Pancreas. 2018;47:183–189.
   PubMed Web of Science ®Google Scholar
• Abbassi R, Schmid RM. Evolving treatment paradigms for pancreatic cancer. Visceral Med. 2019;35(6):362–372. doi:10.1159/000503797.
   PubMed Web of Science ®Google Scholar
• Nami B, Maadi H, Wang Z. Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer. Cancers. 2018;10(10):342. doi:10.3390/cancers10100342.
   PubMed Web of Science ®Google Scholar
• Iwahori K. Cytotoxic CD8+ lymphocytes in the tumor microenvironment. Adv Exp Med Biol. 2020;1224:53–62. doi:10.1007/978-3-030-35723-8_4.
   PubMed Web of Science ®Google Scholar
• van Furth R. Macrophage activity and clinical immunology. Origin and kinetics of mononuclear phagocytes. Ann NY Acad Sci. 1976;278:161–175. doi:10.1111/j.1749-6632.1976.tb47027.x.
   PubMed Web of Science ®Google Scholar
• Gui T, Shimokado A, Sun Y, Akasaka T, Muragaki Y. Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery. Mediators Inflam. 2012;2012:693083. doi:10.1155/2012/693083.
   PubMed Web of Science ®Google Scholar
• Lee HW, Choi HJ, Ha SJ, Lee KT, Kwon YG. Recruitment of monocytes/macrophages in different tumor microenvironments. Biochimica et iophysica cta. 2013;1835(2):170–179. doi:10.1016/j.bbcan.2012.12.007.
   PubMed Web of Science ®Google Scholar
• Wei T, Zhong W, Li Q. Role of heterogeneous regulatory T cells in the tumor microenvironment. Pharmacological esearch. 2020;153:104659. doi:10.1016/j.phrs.2020.104659.
   Google Scholar
• Meng Z, Yuan Q, Zhao J, Wang B, Li S, Offringa R, et al. The m6A-related mRNA signature predicts the prognosis of pancreatic cancer patients. Mol Therapy Oncolytics. 2020;17:460–470. doi:10.1016/j.omto.2020.04.011.
   PubMed Web of Science ®Google Scholar